3.4. Baseline Plasma CRP Values Define a Subset of NP001 Treated ALS Patients Whose Loss in VC over the 6-Month Phase 2A Study Is Markedly Slowed vs. Placebo. This evidence concerns the gene CRP and amyotrophic lateral sclerosis.